Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01843374 · OUTCOME

Duration of Response by Treatment Arm

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma · Source last updated 2026-07-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
Full Range
Time frame
Duration of response from the first documentation of objcetive response (confirmed CR or PR) to the first documented disease progression, assessed up to 14 weeks after the initial response.

What was measured

Duration of response will be defined as the duration from the first documentation of complete response (CR), partial response (PR) to the first documented disease progression.

Analysis population: ITT

Groups in this outcome

TREMELIMUMAB

Tremelimumab 10mg/kg

PLACEBO

Placebo.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TREMELIMUMAB382
PLACEBO189

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
TREMELIMUMAB4.8Not reported013.4Not reported
PLACEBO5.57Not reported2.88.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        13.4
        value
        4.8
      2. group Id
        OG001
        lower Limit
        2.8
        upper Limit
        8.3
        value
        5.57
denom Units Selected
Participants
denoms
  1. counts
    1. group Id
      OG000
      value
      382
    2. group Id
      OG001
      value
      189
    units
    Participants
description
Duration of response will be defined as the duration from the first documentation of complete response (CR), partial response (PR) to the first documented disease progression.
dispersion Type
Full Range
groups
  1. description
    Tremelimumab 10mg/kg
    id
    OG000
    title
    TREMELIMUMAB
  2. description
    Placebo.
    id
    OG001
    title
    PLACEBO
param Type
MEDIAN
population Description
ITT
reporting Status
POSTED
time Frame
Duration of response from the first documentation of objcetive response (confirmed CR or PR) to the first documented disease progression, assessed up to 14 weeks after the initial response.
title
Duration of Response by Treatment Arm
type
SECONDARY
type Units Analyzed
Participants
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice